Biogen Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 07:15PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat with Chris Viehbacher, who joined Biogen a little bit less than 2 months ago as CEO. So Chris, Happy New Year, and thanks for joining us today.

Christopher A. Viehbacher - Biogen Inc. - President, CEO & Director

Thanks. Happy New Year to you.

Questions and Answers:

Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst

So maybe just to kick off. It seems like you're joining a company that's kind of at a crossroads. So you've got, obviously, a very exciting new launch in the Alzheimer's side. We've got a large pipeline, but one I think is viewed as kind of high-risk high reward, and we've got a base business that's got some LOE pressures. So can you talk about the key challenges that you see facing Biogen right now and how your kind of plan to prioritize these as you think about your
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot